Caribou Biosciences to Evaluate Strategic AlternativesGlobeNewsWire · Oct 6, 2026
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research · Sep 14, 2026
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBUDefense World · Sep 4, 2026
Looking for Earnings Beat? Buy These 5 Top-Ranked StocksZacks Investment Research · Aug 31, 2026
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75Defense World · Aug 17, 2026
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 13, 2026Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.32 | -$0.24 | Beat |
| May 7, 2026 | -$0.33 | -$0.26 | Beat |
| Mar 5, 2026 | -$0.33 | -$0.28 | Beat |
| Nov 12, 2025 | -$0.36 | -$0.30 | Beat |
| Aug 12, 2025 | -$0.40 | -$0.35 | Beat |
| May 8, 2025 | -$0.43 | -$0.43 | Beat |